Education
About Us
Working with TipRanks
Follow Us
Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.74
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.74
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.49 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€755.57M
Enterprise Value€958.68M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)37.7
Beta1.01
Next Earnings
May 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,319,600
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.12Price Target Upside51.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSustained and rising free cash flow provides durable financing optionality: it supports debt repayment, shareholder returns, and reinvestment into stores, DTC and product development. Strong cash conversion cushions earnings volatility and funds strategic initiatives without relying on external capital.
Debt Reduction And Manageable LeverageMaterial year-on-year debt reduction and a mid‑range net debt/EBITDA ratio improve financial flexibility and lower interest burden. This durable improvement increases resilience to sales shocks, enables targeted investment in growth channels, and reduces refinancing risk over the medium term.
High Gross Margin StructureA persistently high gross margin reflects premium pricing, brand strength, and favorable product economics, particularly via DTC. This structural margin buffer can absorb cost inflation or markdowns, supporting operating leverage and making sustained profitability achievable if fixed costs are controlled.
Bears Say
Declining Revenue And MarginsA multi-year top-line decline paired with collapsing net margins signals structural demand or mix deterioration. Persistently weak revenue undermines scale economics, constrains reinvestment, and risks eroding brand momentum unless product, pricing or channel strategies deliver sustained recovery.
EMEA DTC Weakness & Product Segment TroubleWeak direct-to-consumer performance in EMEA and persistent issues in core product categories affect the high-margin channel and the brand's iconic offerings. Structural weakness in a large region and key SKUs limits margin recovery and requires multi-quarter assortment, marketing and merchandising fixes to restore durable growth.
Tariff And Cost HeadwindsOngoing tariff costs increase COGS and pressure gross margins unless offset by pricing or sourcing changes. Tariff exposure is structural while trade policies persist, forcing either permanent higher consumer prices or sustained margin compression and complicating international expansion economics.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.49 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €755.57M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 100 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.06.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,319,600 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.556%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.12 (51.35% Upside)
€1.12 (51.35% Upside)
Insider Transactions
Bought Shares
Worth £155.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.12
▲(51.35% Upside)
Technical Analysis
Options Prices
Currently, No data available
---